NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
About
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is a federal funding opportunity from National Institutes of Health. This forecasted grant opportunity (FOR-OD-26-001) is available nationwide for eligible applicants.
The NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed) is a federal funding opportunity designed to support small businesses developing innovative research and development solutions in health and life sciences. This grant is specifically structured for companies that have identified promising research concepts but cannot include clinical trials as part of their proposed work. The program encourages small business entrepreneurs and researchers to transform scientific discoveries into commercially viable products and services that address public health challenges. Eligible applicants should have innovative ideas in areas relevant to NIH, CDC, and FDA priorities, including medical devices, diagnostics, therapeutic approaches, and public health technologies. This funding opportunity is ideal for small business owners seeking federal support to advance their research through the proof-of-concept and commercialization phases. By participating in this SBIR program, entrepreneurs gain access to substantial federal investment, technical expertise, and pathways to bring life-saving innovations to market. The Parent SBIR mechanism (R43/R44) provides a structured two-phase approach to develop and validate innovative solutions. For current funding amounts, eligibility requirements, and application deadlines, applicants should consult the official NIH SBIR website and the specific program announcement (FOR-OD-26-001).
Grant Details
Funding Range
Varies by phase and cycle
Grant Type
Federal
Application Cycle
Annual cycle with specific deadlines per announcement
Best For
Small businesses developing innovative health sciences R&D solutions
Frequently Asked Questions
Who is eligible for the NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?
Eligibility for this SBIR grant is limited to small businesses meeting federal size standards. General SBIR eligibility typically requires that the applicant be a for-profit small business concern with primary operations in the United States. Specific eligibility criteria, ownership requirements, and additional qualifications for this forecasted opportunity (FOR-OD-26-001) should be verified on the official NIH SBIR website, as detailed requirements may apply.
How much funding does the NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed) provide?
Funding amounts vary by grant cycle and phase. The Parent SBIR mechanism typically includes Phase I and Phase II components with different funding levels. For specific funding amounts applicable to this forecasted opportunity (FOR-OD-26-001), applicants should visit the official NIH SBIR portal or contact the National Institutes of Health directly.
How do I apply for the NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?
Applications for this SBIR grant are typically submitted through Grants.gov or the NIH eRA Commons system. The application process generally involves developing a detailed research proposal that demonstrates the innovation, commercial potential, and alignment with NIH, CDC, or FDA research priorities. Applicants should review the specific program announcement (FOR-OD-26-001) on the NIH SBIR website for detailed submission instructions, required forms, deadlines, and technical guidelines before applying.
What can NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed) funding be used for?
This grant supports research and development activities in areas relevant to the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Funding can support innovative R&D projects in health sciences, medical technologies, diagnostic tools, therapeutic development, and public health solutions. However, this specific grant mechanism explicitly does not allow clinical trial activities. Applicants should review the program announcement for detailed guidance on allowable uses and project scope.
Last updated: March 1, 2026